Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis

• Main Authors: Light JG (Author), Su JJ (Author), Feldman SR (Author)
• Format: Book
• Published: Dove Medical Press, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Jeremy G Light,1 Jennifer J Su,1 Steven R Feldman1– 4 1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; 4Department of Dermatology, University of Southern Denmark, Odense, DenmarkCorrespondence: Jeremy G LightDepartment of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USATel [phone]Fax [phone]Email [e-mail]: Psoriasis is a chronic immune-mediated disease involving complex interaction of T cells and keratinocytes. The comprehensive pathogenesis of psoriasis is not fully understood but the IL-23/Th17 axis is a central pathway in driving disease development. Guselkumab is the first treatment of moderate-to-severe psoriasis that specifically targets the p19 subunit of IL-23. The benefit of guselkumab has been established by a number of clinical trials including demonstration of greater long-term efficacy in recent comparator trials. This review addresses the results of head-to-head trials (ECLIPSE, IXORA-R, and POLARIS) that compared guselkumab to secukinumab, ixekizumab, and fumaric acid esters. The previously demonstrated long-term efficacy of guselkumab has been corroborated by many recently published studies. The effective and safe profile, convenient dosing, and improved quality of life in patients make gulselkumab a viable first-line treatment option for moderate-to-severe psoriasis.Keywords: guselkumab, psoriasis, biologics, efficacy, interleukin-23

Item Description

1178-7015